Literature DB >> 22188534

FGFR3, PIK3CA and RAS mutations in benign lichenoid keratosis.

L Groesser1, E Herschberger, M Landthaler, C Hafner.   

Abstract

BACKGROUND: Benign lichenoid keratoses (BLKs) are solitary skin lesions which have been proposed to represent a regressive form of pre-existent epidermal tumours such as solar lentigo or seborrhoeic keratosis. However, the genetic basis of BLK is unknown.
OBJECTIVES: FGFR3, PIK3CA and RAS mutations have been shown to be involved in the pathogenesis of seborrhoeic keratosis and solar lentigo. We thus investigated whether these mutations are also present in BLK.
METHODS: After manual microdissection and DNA isolation, 52 BLKs were screened for FGFR3, PIK3CA and RAS hotspot mutations using SNaPshot(®) multiplex assays.
RESULTS: We identified 6/52 (12%) FGFR3 mutations, 10/52 (19%) PIK3CA mutations, 6/52 (12%) HRAS mutations and 2/52 (4%) KRAS mutations. FGFR3 and RAS mutations were mutually exclusive. One BLK showed a simultaneous PIK3CA and HRAS mutation. In nine BLKs with a mutation, nonlesional control tissue from the epidermal margin and the dermal lymphocytic infiltrate were wild-type, indicating that these mutations are somatic. To demonstrate that these findings are specific, 10 samples of lichen planus were analysed without evidence for FGFR3, PIK3CA or RAS mutations.
CONCLUSIONS: Our results indicate that FGFR3, PIK3CA and RAS mutations are present in approximately 50% of BLKs. These findings support the concept on the molecular genetic level that at least a proportion of BLKs represents regressive variants resulting from former benign epidermal tumours such as seborrhoeic keratosis and solar lentigo.
© 2011 The Authors. BJD © 2011 British Association of Dermatologists 2011.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22188534     DOI: 10.1111/j.1365-2133.2011.10788.x

Source DB:  PubMed          Journal:  Br J Dermatol        ISSN: 0007-0963            Impact factor:   9.302


  14 in total

1.  PI3K/AKT pathway mutations cause a spectrum of brain malformations from megalencephaly to focal cortical dysplasia.

Authors:  Laura A Jansen; Ghayda M Mirzaa; Gisele E Ishak; Brian J O'Roak; Joseph B Hiatt; William H Roden; Sonya A Gunter; Susan L Christian; Sarah Collins; Carissa Adams; Jean-Baptiste Rivière; Judith St-Onge; Jeffrey G Ojemann; Jay Shendure; Robert F Hevner; William B Dobyns
Journal:  Brain       Date:  2015-02-25       Impact factor: 13.501

Review 2.  Mosaic Disorders of the PI3K/PTEN/AKT/TSC/mTORC1 Signaling Pathway.

Authors:  Neera Nathan; Kim M Keppler-Noreuil; Leslie G Biesecker; Joel Moss; Thomas N Darling
Journal:  Dermatol Clin       Date:  2017-01       Impact factor: 3.478

3.  A case report of disappearing pigmented skin lesions associated with pembrolizumab treatment for metastatic melanoma.

Authors:  Z J Wolner; A A Marghoob; M P Pulitzer; M A Postow; M A Marchetti
Journal:  Br J Dermatol       Date:  2017-09-21       Impact factor: 9.302

Review 4.  [Genetic basis of seborrheic keratosis and epidermal nevi].

Authors:  C Hafner; H Hafner; L Groesser
Journal:  Pathologe       Date:  2014-09       Impact factor: 1.011

5.  PIK3CA-related overgrowth spectrum (PROS): diagnostic and testing eligibility criteria, differential diagnosis, and evaluation.

Authors:  Kim M Keppler-Noreuil; Jonathan J Rios; Victoria E R Parker; Robert K Semple; Marjorie J Lindhurst; Julie C Sapp; Ahmad Alomari; Marybeth Ezaki; William Dobyns; Leslie G Biesecker
Journal:  Am J Med Genet A       Date:  2014-12-31       Impact factor: 2.802

6.  Clinical and dermoscopic features associated with lichen planus-like keratoses that undergo skin biopsy: A single-center, observational study.

Authors:  Konstantinos Liopyris; Cristian Navarrete-Dechent; Stephen W Dusza; Ashfaq A Marghoob; Liang Deng; Barbara B Wilson; Michael A Marchetti
Journal:  Australas J Dermatol       Date:  2018-11-18       Impact factor: 2.875

7.  Cutaneous carcinosarcoma: further insights into its mutational landscape through massive parallel genome sequencing.

Authors:  Alberto Paniz-Mondolfi; Rajesh Singh; George Jour; Mandana Mahmoodi; A Hafeez Diwan; Bedia A Barkoh; Ronald Cason; Yve Huttenbach; Gustavo Benaim; John Galbincea; Rajyalakshmi Luthra
Journal:  Virchows Arch       Date:  2014-07-17       Impact factor: 4.064

8.  Circulating Tumor Cells: Who is the Killer?

Authors:  Patrizia Paterlini-Bréchot
Journal:  Cancer Microenviron       Date:  2014-12-20

9.  PIK3CA-associated developmental disorders exhibit distinct classes of mutations with variable expression and tissue distribution.

Authors:  Ghayda Mirzaa; Andrew E Timms; Valerio Conti; Evan August Boyle; Katta M Girisha; Beth Martin; Martin Kircher; Carissa Olds; Jane Juusola; Sarah Collins; Kaylee Park; Melissa Carter; Ian Glass; Inge Krägeloh-Mann; David Chitayat; Aditi Shah Parikh; Rachael Bradshaw; Erin Torti; Stephen Braddock; Leah Burke; Sondhya Ghedia; Mark Stephan; Fiona Stewart; Chitra Prasad; Melanie Napier; Sulagna Saitta; Rachel Straussberg; Michael Gabbett; Bridget C O'Connor; Catherine E Keegan; Lim Jiin Yin; Angeline Hwei Meeng Lai; Nicole Martin; Margaret McKinnon; Marie-Claude Addor; Luigi Boccuto; Charles E Schwartz; Agustina Lanoel; Robert L Conway; Koenraad Devriendt; Katrina Tatton-Brown; Mary Ella Pierpont; Michael Painter; Lisa Worgan; James Reggin; Raoul Hennekam; Karen Tsuchiya; Colin C Pritchard; Mariana Aracena; Karen W Gripp; Maria Cordisco; Hilde Van Esch; Livia Garavelli; Cynthia Curry; Anne Goriely; Hulya Kayserilli; Jay Shendure; John Graham; Renzo Guerrini; William B Dobyns
Journal:  JCI Insight       Date:  2016-06-16

10.  Mouse models of human PIK3CA-related brain overgrowth have acutely treatable epilepsy.

Authors:  Achira Roy; Jonathan Skibo; Franck Kalume; Jing Ni; Sherri Rankin; Yiling Lu; William B Dobyns; Gordon B Mills; Jean J Zhao; Suzanne J Baker; Kathleen J Millen
Journal:  Elife       Date:  2015-12-03       Impact factor: 8.140

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.